No Difference in Disease Markers for IBD Patients Treated With Biosimilars

(MedPage Today) -- There was no difference in drug persistence or other biomarkers among patients with inflammatory bowel disease (IBD) treated with an adalimumab (Humira) biosimilar, U.K. researchers found in an observational cohort study.
After...